==Pacira BioSciences (PCRX) to be acquired by Viatris (VTRS) for $36.50/share cash

Viatris agreed to buy all outstanding Pacira shares for $36.50 each in cash, valuing Pacira's equity at about $1.65 bln.

• Pacira adds marketed non-opioid pain products EXPAREL and ZILRETTA; the company generated about $746 mln of revenue and $177 mln of adjusted EBITDA in the last 12 months ended June 30, 2026.
• Viatris said the deal should expand its U.S. innovative medicines capabilities, be synergistic with its fast-acting meloxicam opportunity, and be immediately accretive to financial guidance metrics.
• The transaction is expected to close by the end of 2026 and Viatris said it preserves financial flexibility under its capital allocation strategy.